Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Hepatogastroenterology 1998;45(21):624-33
Date
07/31/1998Pubmed ID
9684107Scopus ID
2-s2.0-0031853519 (requires institutional sign-in at Scopus site) 9 CitationsAbstract
The goal of multimodality therapy for localized pancreatic cancer is to maximize local-regional disease control and patient survival. In contrast to surgery for other solid tumors, prolonged recovery following pancreaticoduodenectomy may prevent the timely delivery of postoperative adjuvant therapy. Therefore, efforts at The University of Texas, M.D. Anderson Cancer Center have focused on the delivery of chemotherapy and radiation therapy prior to surgery in patients with localized pancreatic cancer. Clinical trials have emphasized the use of altered-fractionation schedules of radiation therapy combined with novel radiation-sensitizing agents. All treatment schemes aim to decrease toxicity and treatment time while improving therapeutic efficacy.
Author List
Miller AR, Pisters PW, Lee JE, Janjan NA, Abbruzzese JL, Evans DBAuthor
Douglas B. Evans MD Chair, Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdenocarcinomaChemotherapy, Adjuvant
Clinical Trials as Topic
Combined Modality Therapy
Humans
Neovascularization, Pathologic
Paclitaxel
Pancreatic Neoplasms
Pancreaticoduodenectomy
Preoperative Care
Radiation-Sensitizing Agents
Radiotherapy, Adjuvant
Treatment Outcome
